Navigation Links
Scientific evidence of health problems from past contamination of drinking water at Camp Lejeune is limited and unlikely to be resolved with further study
Date:6/15/2009

ast, bladder, kidneys, esophagus, and lungs. This categorization means these epidemiologic studies give some reason to be concerned that sufficiently high levels of TCE or PCE may have an adverse effect, but the studies do not provide strong evidence that they actually do.

The majority of the health outcomes reviewed in the epidemiologic studies was placed in the category of "inadequate or insufficient evidence," meaning that evidence was of insufficient quantity, quality, or inconclusive in results to make an informed assessment, but that an association between exposure to a specific agent and a health outcome cannot be ruled out. A summary of the conclusions drawn from the epidemiologic studies related to solvent exposure can be found in Box 2 on page 8 of the report. Some health outcomes reported by former residents of the base -- such as male breast cancer and second-generation effects -- are not cited because those specific outcomes were not investigated or the studies were too small or of insufficient quality.

The committee also compared information from epidemiologic studies with that from toxicologic studies and found similar health effects in both humans and animals for kidney cancer. Similar noncancerous diseases and disorders included adverse effects on the liver, kidneys, and nervous and immune systems. The findings are in Table 1 on page 10. The absence of other diseases and disorders from Table 1 indicate that the findings were inconsistent between the epidemiologic and toxicologic evidence or were not addressed in the available studies.

Studies specifically on the Camp Lejeune population have addressed only reproductive health outcomes, but the limited quality of exposure information restricts their value. The inability to study exposure and health outcomes accurately is a serious limitation in any future research. Thus, the committee concluded that the U.S. Department of the Navy, under which the Marine Corps op
'/>"/>

Contact: Jennifer Walsh
news@nas.edu
202-334-2138
National Academy of Sciences
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. USC researchers present diabetes findings at American Diabetes Association Scientific Sessions
2. SRI International announces findings from new upper atmospheric radar system for scientific research
3. Woods Hole lecture series explores range of scientific topics
4. UC Riverside professor receives top scientific honor
5. Virginia Tech graduate student receives first Rachel Carson award for scientific excellence
6. Business, scientific, higher education groups laud President Obamas commitment to science
7. 3 Woods Hole scientific institutions forge alliance to address societal issues
8. Meet-the-expert sessions on 20 key topics to enhance scientific programme of IOFWCO-ECCEO10
9. 200,000 rice mutants available worldwide for scientific investigation
10. APS commends President Obamas memorandum on scientific integrity
11. 200,000 rice mutants available worldwide for scientific investigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Although Antarctic krill (Euphausia superba) are one of the ... their life cycle have remained murky. , Understanding krill ... birds, and marine mammals, yet they are vulnerable to ... issue of BioScience, the monthly journal of the American ...
... Division of Cellegy Pharmaceuticals, Inc. today announced a non-exclusive ... the prevention of HIV and other sexually transmitted diseases. ... the agreement are in various stages of development and ... Savvy, which is currently in Phase III clinical trials ...
... five percent of deaths from SIDS (sudden infant death syndrome) ... gene and half of those deaths result from a common ... abnormal heart rhythm during times of environmental stress, a research ... February 2006 issue of the Journal of Clinical Investigation. ...
Cached Biology News:New licensing agreement to maximize AIDS drug development 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
(Date:6/2/2015)... SAO PAULO , June 2, 2015   ... leader in biosimilars, today announced that its partner, Celltrion – ... ANVISA – the National Health Surveillance Agency in ... first biosimilar monoclonal antibody approved for use in ... by Hospira. Hospira also markets and sells biosimilar infliximab ...
(Date:6/2/2015)... LOUIS , June 2, 2015   ... Life Science and Technology company, announced today it ... Science to launch genetically engineered human neural ... advance the research of neurological diseases. These new ... provide unique and versatile tools for the study ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: